An Overview of the Use of Recovered Plasma in the Treatment and Prevention of Covid-19.

Abstract

Novel coronavirus disease 2019 (COVID -19) has prompted a reevaluation of the efficacy of
traditional convalescent plasma transfusion (CPT) since no particular antiviral medicines have yet been
authorized for this virus. Since it has been shown that polyclonal neutralizing antibodies may shorten the duration
of viremia, convalescent plasma therapy has been used to treat infectious diseases since the early 1900s.
According to the facts we have, (a) is the most important result. Patients in critical care who get convalescent
plasma treatment have a lower rate of death. (b). Clinical symptoms improved after receiving convalescent
plasma. (c).Following CPT treatment, an increase in neutralizing antibody titers and a loss of SARS-CoV-2 RNA
were seen in almost all patients. In this paper, we explore some of the Convalescent plasma therapy (CPT) for the
treatment of COVID-19: an overview of its background, definition, mechanism of action, production,
formulation, and therapeutic applications. Potential Risk, Risk Benefit Analysis, Optimal Dosing, Transfusion,
and Convalescent Plasma.